Published in Curr Opin Rheumatol on September 01, 2007
Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis. Arthritis Res Ther (2009) 1.26
Genomic characterization of remission in juvenile idiopathic arthritis. Arthritis Res Ther (2013) 0.87
Predictors of response to methotrexate in juvenile idiopathic arthritis. Pediatr Rheumatol Online J (2014) 0.85
MRI of the wrist in juvenile idiopathic arthritis: erosions or normal variants? A prospective case-control study. Pediatr Radiol (2013) 0.85
HLA B27 allele types in homogeneous groups of juvenile idiopathic arthritis patients in Latvia. Pediatr Rheumatol Online J (2010) 0.81
Dynamic tracking of functional gene modules in treated juvenile idiopathic arthritis. Genome Med (2015) 0.80
Assessment of the body composition and parameters of the cardiovascular risk in juvenile idiopathic arthritis. Biomed Res Int (2015) 0.78
Erosion or normal variant? 4-year MRI follow-up of the wrists in healthy children. Pediatr Radiol (2015) 0.77
Juvenile Idiopathic Arthritis. Balkan Med J (2017) 0.75
Role of adalimumab in the management of children and adolescents with juvenile idiopathic arthritis and other rheumatic conditions. Adolesc Health Med Ther (2012) 0.75
Achievement of clinical remission in patients with juvenile idiopathic arthritis under a 2-10-year Etanercept exposure. Clin Rheumatol (2013) 0.75
Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet (2008) 3.00
Dense genotyping of immune-related disease regions identifies 14 new susceptibility loci for juvenile idiopathic arthritis. Nat Genet (2013) 2.60
Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum (2008) 2.56
Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum (2004) 2.31
Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) (2012) 2.21
Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma. Arthritis Care Res (Hoboken) (2012) 1.84
Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. Arthritis Rheumatol (2014) 1.51
Very high serum ferritin levels are associated with increased mortality and critical care in pediatric patients. Pediatr Crit Care Med (2011) 1.51
Developing standards of care for patients with juvenile idiopathic arthritis. Rheumatology (Oxford) (2010) 1.51
Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum (2003) 1.42
Old challenges and new directions in pediatric rheumatology. J Rheumatol (2006) 1.40
An i2b2-based, generalizable, open source, self-scaling chronic disease registry. J Am Med Inform Assoc (2012) 1.39
Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken) (2012) 1.33
Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference. Arthritis Care Res (Hoboken) (2010) 1.32
Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis. Arthritis Res Ther (2009) 1.26
Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum (2006) 1.16
Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis. Arthritis Rheum (2013) 1.13
Inactive disease in polyarticular juvenile idiopathic arthritis: current patterns and associations. Rheumatology (Oxford) (2009) 1.10
Preliminary validation and clinical meaning of the Cutaneous Assessment Tool in juvenile dermatomyositis. Arthritis Rheum (2008) 1.09
Monitoring the long-term safety of therapies for children with juvenile idiopathic arthritis: time for a consolidated patient registry. Arthritis Care Res (Hoboken) (2010) 1.06
Polysomnography and self-reported sleep, pain, fatigue, and anxiety in children with active and inactive juvenile rheumatoid arthritis. J Pediatr Psychol (2007) 1.06
Summary of worldwide pediatric malignancies reported after exposure to etanercept. Pediatr Rheumatol Online J (2010) 1.03
Sleep disturbance, daytime sleepiness, and neurocognitive performance in children with juvenile idiopathic arthritis. Sleep (2010) 1.01
Health-related quality of life, physical function, fatigue, and disease activity in children with established polyarticular juvenile idiopathic arthritis. J Rheumatol (2009) 1.00
Gene expression profiling in neutrophils from children with polyarticular juvenile idiopathic arthritis. Arthritis Rheum (2009) 1.00
Hierarchy of risk of childhood-onset rheumatoid arthritis conferred by HLA-DRB1 alleles encoding the shared epitope. Arthritis Rheum (2012) 0.98
Disease activity assessment in childhood vasculitis: development and preliminary validation of the Paediatric Vasculitis Activity Score (PVAS). Ann Rheum Dis (2012) 0.97
Intraarticular corticosteroid injections of the temporomandibular joint in juvenile idiopathic arthritis. J Rheumatol (2008) 0.95
Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) (2013) 0.95
Susceptibility to childhood-onset rheumatoid arthritis: investigation of a weighted genetic risk score that integrates cumulative effects of variants at five genetic loci. Arthritis Rheum (2013) 0.93
Performance of rheumatoid arthritis disease activity measures and juvenile arthritis disease activity scores in polyarticular-course juvenile idiopathic arthritis: Analysis of their ability to classify the American College of Rheumatology pediatric measures of response and the preliminary criteria for flare and inactive disease. Arthritis Care Res (Hoboken) (2010) 0.90
Development and retrospective validation of the juvenile spondyloarthritis disease activity index. Arthritis Care Res (Hoboken) (2014) 0.88
Whole blood gene expression profiling predicts therapeutic response at six months in patients with polyarticular juvenile idiopathic arthritis. Arthritis Rheumatol (2014) 0.87
Normal scores for nine maneuvers of the Childhood Myositis Assessment Scale. Arthritis Rheum (2004) 0.86
Remission in juvenile idiopathic arthritis: current facts. Curr Rheumatol Rep (2010) 0.86
Heterotopic ossification of the temporomandibular joint in juvenile idiopathic arthritis. J Rheumatol (2011) 0.85
Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum (2010) 0.85
Disease activity and fatigue in juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) (2013) 0.85
Using registries to identify adverse events in rheumatic diseases. Pediatrics (2013) 0.83
Evolution of paediatric-specific vasculitis classification criteria. Ann Rheum Dis (2010) 0.83
Algorithm development for corticosteroid management in systemic juvenile idiopathic arthritis trial using consensus methodology. Pediatr Rheumatol Online J (2012) 0.82
Tumor necrosis factor inhibitors in the management of juvenile idiopathic arthritis: an evidence-based review. Paediatr Drugs (2010) 0.82
Sleep disturbances and neurobehavioral functioning in children with and without juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) (2011) 0.81
Juvenile idiopathic arthritis in relation to maternal prenatal smoking. Arthritis Care Res (Hoboken) (2015) 0.80
Randomized, double-blind, dose-escalation trial of triptorelin for ovary protection in childhood-onset systemic lupus erythematosus. Arthritis Rheumatol (2015) 0.79
Characterisation of gamma delta (γδ) T cell populations in patients with sepsis. Cell Biol Int (2014) 0.77
Novel method to collect medication adverse events in juvenile arthritis: results from the childhood arthritis and rheumatology research alliance enhanced drug safety surveillance project. Arthritis Care Res (Hoboken) (2015) 0.77
Injectable tumor necrosis factor α inhibitors and outpatient antimicrobial use in children with rheumatic diseases: analyses of prescription claims from a pharmacy benefit manager database. Arthritis Care Res (Hoboken) (2013) 0.77
Perinatal exposures and Kawasaki disease in Washington State: a population-based, case-control study. Pediatr Infect Dis J (2012) 0.77
Developing women leaders in medicine at the grass roots level: evolution from skills training to institutional change. J Pediatr (2007) 0.75
Methotrexate and injectable tumor necrosis factor-α inhibitor adherence and persistence in children with rheumatic diseases. J Rheumatol (2012) 0.75
HACCP-based food safety management systems: great in theory but can we really make them work in practice? Perspect Public Health (2014) 0.75
The food safety impact of salt and sodium reduction initiatives. Perspect Public Health (2014) 0.75